Watch BTAIQ. Know when insiders buy.
One email the day a filing lands. Free.
BTAIQ
BioXcel Therapeutics, Inc.
0.01
+0.00 +0.00%
USD · close Oct 30
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $407KP/E —DIV YIELD —FCF YIELD -12508.00%REV TTM $742K −14.5%NET INCOME −$70.9MNET DEBT $91.6M52W 0.01 – 2.25SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $182K | +51.7% | 87.9% | −$10.2M | −$14.7M | — | -0.49 | −$6.1M | $0 | −$6.1M | Aug 13 |
| Q1 2026 · Mar 31 | $206K | +22.6% | -37.4% | −$10.2M | −$12.7M | — | -0.54 | −$11.8M | $0 | −$11.8M | Aug 13 |
| Q4 2025 · Dec 31derived | $256K | −30.1% | 87.5% | −$10.3M | −$12.5M | — | 0.65 | −$14.2M | $0 | −$14.2M | Mar 27 |
| Q3 2025 · Sep 30 | $98K | −54.2% | 88.8% | −$14.2M | −$30.9M | — | -2.18 | −$18.8M | $0 | −$18.8M | Nov 12 |
| Q2 2025 · Jun 30 | $120K | −89.1% | 10.8% | −$15.9M | −$19.2M | — | -2.45 | −$12.6M | $0 | −$12.6M | Aug 13 |
| Q1 2025 · Mar 31 | $168K | −71.1% | 91.7% | −$10.1M | −$7.3M | — | -1.50 | −$12M | $0 | −$12M | Aug 13 |
| Q4 2024 · Dec 31derived | $366K | −2.7% | -127.3% | −$10.5M | −$10.9M | — | -2.91 | −$14.8M | $0 | −$14.8M | Mar 27 |
| Q3 2024 · Sep 30 | $214K | −37.2% | -446.7% | −$15.3M | −$13.7M | — | -5.15 | −$16.3M | $0 | −$16.3M | Nov 12 |
| Q2 2024 · Jun 30 | $1.1M | — | 94.4% | −$17.3M | −$8.3M | — | -3.30 | −$23.2M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | $582K | — | 86.3% | −$24.2M | −$26.8M | — | -13.89 | −$17.7M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $376K | — | -89.9% | −$19.9M | −$22.3M | — | -92.93 | −$26.9M | $0 | −$26.9M | Mar 28 |
| Q3 2023 · Sep 30 | $341K | — | -50.1% | −$48.3M | −$50.5M | — | -1.72 | −$37.6M | $0 | −$37.6M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $642K | 74.5% | −$50.5M | −$69.9M | -10887.4% | -5.73 | −$57.6M | $0 | −$57.6M | — | — |
| FY2024 · to Dec 31 | $2.3M | 5.4% | −$67.2M | −$59.6M | -2630.1% | -23.51 | −$72M | $0 | −$72M | — | — |
| FY2023 · to Dec 31 | $1.4M | 8.7% | −$171.8M | −$179.1M | -12974.9% | -98.33 | −$155M | $20K | −$155M | — | — |
| FY2022 · to Dec 31 | $375K | 94.7% | −$159.6M | −$165.8M | -44201.9% | -5.92 | −$135.3M | $139K | −$135.5M | — | — |
| FY2021 · to Dec 31 | — | — | −$106.9M | −$106.9M | — | -4.05 | −$82.2M | $445K | −$82.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$82.3M | −$82.2M | — | -3.79 | −$66.3M | $316K | −$66.7M | $9M | — |
Every number comes from BioXcel Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.